Return-on-Tangible-Equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Illumina's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2022 was $344 Mil. Illumina's average shareholder tangible equity for the quarter that ended in Mar. 2022 was $475 Mil. Therefore, Illumina's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2022 was 72.42%.
The historical rank and industry rank for Illumina's Return-on-Tangible-Equity or its related term are showing as below:
ILMN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 17.98 Med: 37.08 Max: 78.32
Current: 38.73
During the past 13 years, Illumina's highest Return-on-Tangible-Equity was 78.32%. The lowest was 17.98%. And the median was 37.08%.
ILMN's Return-on-Tangible-Equity is ranked better than 72.69% of 216
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.30
vs ILMN: 38.73
Illumina Return-on-Tangible-Equity Historical Data
The historical data trend for Illumina's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Return-on-Tangible-Equity
48.63
36.35
31.38
17.98
37.80
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Return-on-Tangible-Equity
15.58
18.63
60.44
171.98
72.42
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Return-on-Tangible-Equity Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Illumina's Return-on-Tangible-Equity falls into.
Illumina Return-on-Tangible-Equity Calculation
Illumina's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net income attributable to common stockholders is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Illumina Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Illumina's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.24(0.1%) Volume: 461,260 11:45AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
